Search results for "Rectal Cancer"

showing 10 items of 978 documents

Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013

MaleOncologyOrganoplatinum CompoundsOxaloacetatesColorectal cancerLeucovorinColonoscopyChromosome DisordersDeoxycytidineRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsIntestinal MucosaSigmoidoscopyEarly Detection of Cancermedicine.diagnostic_testFollow up studiesColonoscopyHematologyEuropeClinical PracticeTreatment OutcomeOncologyDiagnosis treatmentChemotherapy AdjuvantLymphatic MetastasisOccult BloodColonic NeoplasmsFemaleFluorouracilChromosome Deletionmedicine.drugRiskmedicine.medical_specialtyAntineoplastic AgentsRisk AssessmentCapecitabineInternal medicinemedicineHumansCapecitabineNeoplasm Stagingbusiness.industryGeneral surgeryCancerSigmoidoscopymedicine.diseaseCarcinoembryonic AntigenNeoplasm Recurrence LocalChromosomes Human Pair 18businessFollow-Up StudiesAnnals of Oncology
researchProduct

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

2012

Background: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates. Methodology/Principal Findings: KRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy da…

MaleOncologyOrganoplatinum Compoundsendocrine system diseasesEpidemiologyColorectal cancer:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]DeoxycytidineMetastasis:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Antineoplastic Combined Chemotherapy ProtocolsPathologyMedicineNeoplasm Metastasisgeneslcsh:Sciencemediana edad:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [Medical Subject Headings]Aged 80 and overanciano:Chemicals and Drugs::Organic Chemicals::Organometallic Compounds::Organoplatinum Compounds [Medical Subject Headings]Cancer Risk FactorsClinical Pharmacologyprotocolos de quimioterapia antineoplásica combinadaColon AdenocarcinomaPronósticoCombination chemotherapyadultoPrognosisBevacizumabOxaliplatinpronósticoOncologyMedicineOncology Agentsmedicine.medical_specialty:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]FluorouraciloBevacizumab:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Cytidine::Deoxycytidine [Medical Subject Headings]:Check Tags::Male [Medical Subject Headings]Molecular GeneticsCapecitabine:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies Monoclonal::Antibodies Monoclonal Humanized [Medical Subject Headings]Gastrointestinal TumorsGenetics:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]HumansClinical TrialsBiologyneoplasmsCapecitabineAgedlcsh:R:Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings]:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes Neoplasm::Oncogenes::Proto-Oncogenes::Genes ras [Medical Subject Headings]medicine.diseasedigestive system diseasesOxaliplatin:Check Tags::Female [Medical Subject Headings]PharmacogeneticsMutationlcsh:QfluorouraciloMultivariate analysisDesoxicitidinahumanosCancer Treatment:Named Groups::Persons::Age Groups::Adult::Aged::Aged 80 and over [Medical Subject Headings]lcsh:Medicinemedicine.disease_causeNeoplasias colorrectalesSurgical oncologyBasic Cancer Research:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Pyrimidinones::Uracil::Fluorouracil [Medical Subject Headings]Clinical Trials (Cancer Treatment)metástasis neoplásicaMetástasis neoplásicaMultidisciplinaryMiddle AgedGenetic EpidemiologyProtocolos de quimioterapia antineoplásica combinadaFemaleAntiangiogenesis TherapyFluorouracilKRASColorectal NeoplasmsResearch Articlemedicine.drugAdultDrugs and DevicesClinical Pathologyneoplasias colorrectalesClinical Research DesignGenetic Causes of CancerAntibodies Monoclonal HumanizedAntibodiesRectal CancerAntibody TherapyDiagnostic MedicineInternal medicine:Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]mutaciónClinical GeneticsMutaciónbusiness.industryPharmacoepidemiologyCancers and NeoplasmsHuman GeneticsChemotherapy and Drug TreatmentdesoxicitidinaGenes rasanticuerposGenetics of Diseasebusinesscompuestos organoplatinoPLoS ONE
researchProduct

Extending neoadjuvant chemotherapy in rectal cancer

2015

Lancet Oncology, The - In Press.Proof corrected by the author Available online since jeudi 16 juillet 2015

MaleOncologymedicine.medical_specialtyChemotherapyRectal NeoplasmsColorectal cancerbusiness.industrymedicine.medical_treatmentChemoradiotherapy AdjuvantAdenocarcinomamedicine.diseaseNeoadjuvant TherapyArticleOncologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdenocarcinomaFemalebusinessNeoadjuvant therapyThe Lancet Oncology
researchProduct

Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer

2015

Modern chemotherapy aims to improve long-term survival for selected patients with peritoneal carcinomatosis. Publications suggest promising results, but the spread of these new aggressive treatment strategies in the general population is not well known.The aim of this study was to draw a picture of epidemiology, management, and survival in synchronous and metachronous peritoneal carcinomatosis from colorectal cancer.The cumulative risk of metachronous peritoneal carcinomatosis was estimated in patients resected for cure. Net survival rates were calculated for synchronous and metachronous peritoneal carcinomatosis.The study was conducted with the use of the Burgundy Digestive Cancer Registry…

MaleOncologymedicine.medical_specialtyColorectal cancerPopulationAntineoplastic AgentsAdenocarcinomaInternal medicineEpidemiologymedicineCarcinomaHumansRegistrieseducationSurvival ratePeritoneal NeoplasmsAgedRetrospective Studieseducation.field_of_studybusiness.industryCarcinomaGastroenterologyRetrospective cohort studyCytoreduction Surgical ProceduresGeneral MedicinePrognosismedicine.diseaseAdenocarcinoma MucinousSurvival RateAdenocarcinomaFemaleObservational studyFrancePeritoneumColorectal NeoplasmsbusinessDiseases of the Colon & Rectum
researchProduct

Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal c…

2006

BACKGROUND: The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer. PATIENTS AND METHODS: Previously untreated patients with metastatic colorectal cancer received raltitrexed 2 mg/m(2) i.v. plus levofolinic acid and 5-fluorouracil according to the De Gramont' schedule given every 2 weeks as first-line chemotherapy. Patients were re-evaluated after six cycles and chemotherapy was continued up to tolerance or disease progression. RESULTS: Seventy patients aged >/=65 years were accrued from 11 centers between September 2001 and …

MaleOncologymedicine.medical_specialtyColorectal cancerfolinic acidmedicine.medical_treatmentLeucovorincolorectal cancerThiophenesAdenocarcinomaNeutropeniaGastroenterologyDrug Administration ScheduleFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans5-fluorouracilNeoplasm MetastasisAgedAged 80 and overChemotherapybusiness.industryraltitrexedHematologymedicine.diseaseRegimenOncologyFluorouracilmetastaseQuinazolinesFemaleFluorouracilNeoplasm Recurrence LocalColorectal NeoplasmsbusinessRaltitrexedmedicine.drugAnnals of Oncology
researchProduct

A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.

2010

Summary Background Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions. The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers. Methods The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries. Data were collected using a standardized procedure. Results Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.…

MaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPerforation (oil well)Population[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaSampling Studies[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRegistries030212 general & internal medicineStage (cooking)educationAgedAged 80 and overPatient Care TeamChemotherapyeducation.field_of_studybusiness.industryAge FactorsGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgeryClinical trialChemotherapy AdjuvantIntestinal Perforation030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisPopulation studyFemaleFrancebusinessIntestinal Obstruction
researchProduct

Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer

2014

Colorectal cancer (CRC) is one of the most common cancers worldwide with high mortality rates. MicroRNAs (miRNAs) have an established role in the development of different cancers. Single nucleotide polymorphisms (SNPs) in miRNA related genes were linked with various gastrointestinal malignancies. However, the data on association between miRNA SNPs and CRC development are inconsistent. The aim of the present study was to evaluate the association between miRNA-related gene polymorphisms (miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608) and the presence of CRC in European population. Gene polymorphisms were analyzed in 621 subjects (controls: n = 428; CRC: n = 193). MiR-27a T>C (rs895819), …

MaleOncologymedicine.medical_specialtyGenotypeColorectal cancerSingle-nucleotide polymorphismLower riskPolymorphism Single NucleotideWhite PeopleArticleGene FrequencyRisk FactorsInternal medicinemicroRNAGenotypeOdds RatioHumansMedicineAlleleGeneAllelesAgedGeneticsMultidisciplinarybusiness.industryOdds ratioMiddle Agedmedicine.diseaseMicroRNAsCase-Control StudiesFemaleColorectal NeoplasmsbusinessScientific Reports
researchProduct

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-…

2009

Abstract Background This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation. Patients and methods The study comprised two parts: a 6-week cetuximab monotherapy dose-escalation phase and a subsequent combination therapy phase, during which patients received cetuximab, at the same dose/schedule as in the monotherapy phase, followed by irinotecan plus infusional 5-fluorouracil/folinic acid (FOLFIRI). Patients in the control group received cetuximab as a 400 mg/m…

MaleOncologymedicine.medical_specialtyMaximum Tolerated DoseCombination therapyColorectal cancerLeucovorinCetuximabAntibodies Monoclonal HumanizedIrinotecanImmunoenzyme TechniquesFolinic acidPharmacokineticsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTissue DistributionneoplasmsAgedDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseasedigestive system diseasesSurgeryErbB ReceptorsSurvival RateIrinotecanTreatment OutcomeOncologyPharmacodynamicsFOLFIRICamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal canc…

2009

Abstract Background: Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy. No standard schedule of irinotecan has been established in this situation. Patients and methods: Metastatic colorectal cancer patients included in the OPTIMOX1 phase III study received first-line oxaliplatin-based chemotherapy (FOLFOX). No second line was defined in the protocol, but data concerning second line were prospectively registered. Inclusion criterion was patients receiving an irinotecan-based second-line chemotherapy. Second-line progression-free survival (PFS) and tumor response were evaluated according to type of irino…

MaleOncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLeucovorinIrinotecanBolus (medicine)FOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTreatment FailureneoplasmsChemotherapybusiness.industryHematologyMiddle Agedmedicine.diseasedigestive system diseasesOxaliplatinOxaliplatinIrinotecanRegimenTreatment OutcomeOncologyFOLFIRICamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Long-term Net Survival in Patients With Colorectal Cancer in France

2013

Net survival, the survival that might occur if cancer was the only cause of death, is a major epidemiological indicator. Recent findings have shown that the classical methods used for the estimation of net survival from cancer registry data, referred as to "relative-survival methods," provided biased estimates.The aim of this study was to provide, for the first time, long-term net survival rates for colorectal cancer by using a population-based digestive cancer registry.This study is a population-based cancer registry analysis. The recently proposed unbiased nonparametric Pohar-Perme estimator was used.Overall, 14,715 colorectal cancers diagnosed between 1976 and 2005 and registered in the …

MaleOncologymedicine.medical_specialtyPathologyTime FactorsColorectal cancerStatistics NonparametricBiasInternal medicineEpidemiologymedicineHumansRegistriesSurvival rateSurvival analysisAgedNeoplasm StagingRetrospective StudiesCause of deathAged 80 and overbusiness.industryAge FactorsGastroenterologyCancerRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisCancer registrySurvival RateFemaleFranceColorectal NeoplasmsbusinessDiseases of the Colon & Rectum
researchProduct